First Time Loading...

Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 2.11 USD -1.4% Market Closed
Updated: May 19, 2024

Intrinsic Value

CGEN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. [ Read More ]

The intrinsic value of one CGEN stock under the Base Case scenario is 1.84 USD. Compared to the current market price of 2.11 USD, Compugen Ltd is Overvalued by 13%.

Key Points:
CGEN Intrinsic Value
Base Case
1.84 USD
Overvaluation 13%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Compugen Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CGEN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Compugen Ltd

Provide an overview of the primary business activities
of Compugen Ltd.

What unique competitive advantages
does Compugen Ltd hold over its rivals?

What risks and challenges
does Compugen Ltd face in the near future?

Summarize the latest earnings call
of Compugen Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Compugen Ltd.

Provide P/S
for Compugen Ltd.

Provide P/E
for Compugen Ltd.

Provide P/OCF
for Compugen Ltd.

Provide P/FCFE
for Compugen Ltd.

Provide P/B
for Compugen Ltd.

Provide EV/S
for Compugen Ltd.

Provide EV/GP
for Compugen Ltd.

Provide EV/EBITDA
for Compugen Ltd.

Provide EV/EBIT
for Compugen Ltd.

Provide EV/OCF
for Compugen Ltd.

Provide EV/FCFF
for Compugen Ltd.

Provide EV/IC
for Compugen Ltd.

Show me price targets
for Compugen Ltd made by professional analysts.

What are the Revenue projections
for Compugen Ltd?

How accurate were the past Revenue estimates
for Compugen Ltd?

What are the Net Income projections
for Compugen Ltd?

How accurate were the past Net Income estimates
for Compugen Ltd?

What are the EPS projections
for Compugen Ltd?

How accurate were the past EPS estimates
for Compugen Ltd?

What are the EBIT projections
for Compugen Ltd?

How accurate were the past EBIT estimates
for Compugen Ltd?

Compare the revenue forecasts
for Compugen Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Compugen Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Compugen Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Compugen Ltd compared to its peers.

Compare the P/E ratios
of Compugen Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Compugen Ltd with its peers.

Analyze the financial leverage
of Compugen Ltd compared to its main competitors.

Show all profitability ratios
for Compugen Ltd.

Provide ROE
for Compugen Ltd.

Provide ROA
for Compugen Ltd.

Provide ROIC
for Compugen Ltd.

Provide ROCE
for Compugen Ltd.

Provide Gross Margin
for Compugen Ltd.

Provide Operating Margin
for Compugen Ltd.

Provide Net Margin
for Compugen Ltd.

Provide FCF Margin
for Compugen Ltd.

Show all solvency ratios
for Compugen Ltd.

Provide D/E Ratio
for Compugen Ltd.

Provide D/A Ratio
for Compugen Ltd.

Provide Interest Coverage Ratio
for Compugen Ltd.

Provide Altman Z-Score Ratio
for Compugen Ltd.

Provide Quick Ratio
for Compugen Ltd.

Provide Current Ratio
for Compugen Ltd.

Provide Cash Ratio
for Compugen Ltd.

What is the historical Revenue growth
over the last 5 years for Compugen Ltd?

What is the historical Net Income growth
over the last 5 years for Compugen Ltd?

What is the current Free Cash Flow
of Compugen Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Compugen Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Compugen Ltd

Current Assets 114.6m
Cash & Short-Term Investments 50.7m
Receivables 63.5m
Other Current Assets 365k
Non-Current Assets 6.8m
Long-Term Investments 3m
PP&E 2.5m
Other Non-Current Assets 1.2m
Current Liabilities 26.3m
Accounts Payable 14.5m
Accrued Liabilities 632k
Other Current Liabilities 11.1m
Non-Current Liabilities 29.5m
Other Non-Current Liabilities 29.5m
Efficiency

Earnings Waterfall
Compugen Ltd

Revenue
33.5m USD
Cost of Revenue
-2m USD
Gross Profit
31.5m USD
Operating Expenses
-44.4m USD
Operating Income
-13m USD
Other Expenses
-5.8m USD
Net Income
-18.8m USD

Free Cash Flow Analysis
Compugen Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

CGEN Profitability Score
Profitability Due Diligence

Compugen Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROIC is Increasing
29/100
Profitability
Score

Compugen Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

CGEN Solvency Score
Solvency Due Diligence

Compugen Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

Compugen Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CGEN Price Targets Summary
Compugen Ltd

Wall Street analysts forecast CGEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CGEN is 5.44 USD with a low forecast of 4.04 USD and a high forecast of 7.35 USD.

Lowest
Price Target
4.04 USD
91% Upside
Average
Price Target
5.44 USD
158% Upside
Highest
Price Target
7.35 USD
248% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Compugen Ltd

Shareholder Return

CGEN Price
Compugen Ltd

1M 1M
+11%
6M 6M
+225%
1Y 1Y
+178%
3Y 3Y
-74%
5Y 5Y
-39%
10Y 10Y
-74%
Annual Price Range
2.11
52w Low
0.53
52w High
2.95
Price Metrics
Average Annual Return 9.39%
Standard Deviation of Annual Returns 97.7%
Max Drawdown -97%
Shares Statistics
Market Capitalization 188.3m USD
Shares Outstanding 89 530 200
Percentage of Shares Shorted 2.25%

CGEN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Compugen Ltd Logo
Compugen Ltd

Country

Israel

Industry

Life Sciences Tools & Services

Market Cap

188.3m USD

Dividend Yield

0%

Description

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Contact

Holon
Azrieli Center, 26 Harokmim St. Bldg D
+97237658585.0
http://www.cgen.com/

IPO

2000-08-01

Employees

73

Officers

CEO, President & Director
Dr. Anat Cohen-Dayag Ph.D.
Senior Vice President of Technology Innovation
Dr. Zurit Levine Ph.D.
Vice President of Preclinical Development
Dr. Pierre Ferre Ph.D.
Chief Financial Officer
Mr. Alberto Sessa
Chief Scientific Officer
Dr. Eran Ophir Ph.D.
Head of Investor Relations & Corporate Communications
Ms. Yvonne Naughton
Show More
General Counsel & Corporate Secretary
Mr. Eran Ben Dor
Vice President of Human Resources
Ms. Dorit Amitay
Senior VP & Senior Advisor of Data and Informatics Solutions
Dr. Yaron Turpaz M.B.A., Ph.D.
Vice President Research and Discovery
Rivka Schwartz
Show Less

See Also

Discover More
What is the Intrinsic Value of one CGEN stock?

The intrinsic value of one CGEN stock under the Base Case scenario is 1.84 USD.

Is CGEN stock undervalued or overvalued?

Compared to the current market price of 2.11 USD, Compugen Ltd is Overvalued by 13%.